John Eastman
John Eastman
Send Message
John Eastman
Stop FollowingJohn Eastman
View as an RSS Feed
View John Eastman's Articles BY TICKER:
- Trius Therapeutics Is A Strong Investment Short And Long Term
- The Validity And Risk Of Keryx Biopharmaceuticals
- Now Is The Time To Pay Attention To InVivo
- Is Now The Time To Jump Into Halozyme?
- Google, Microsoft, And Apple Are Likely Using Technology Held By Mobivity Holdings
- Why The Trius Offering Is A Positive Move
- The Upward Climb Of Halozyme Therapeutics
- Looking At Dendreon Again
- What Is Keryx Biopharmaceuticals And Why Does It Matter?
- Trius Quickens Pace Towards Commercialization With FDA Designation For Tedizolid Phosphate
- Halozyme Therapeutics's Key Deal With Pfizer Is Significant
- Trius Therapeutics: A Long, Stable, And Steady Play
- The Company You Keep Speaks Volumes: Novabay And Trius
- Trius Therapeutics: Slow, Steady And Cerebral
- Fall Catalysts To Watch
- A 1-Day Snapshot Of Firms Related To The Apple-Samsung Electronics Case
- What Is Nuance Communications, And Why Does It Matter?
- Novabay Pharmaceuticals, Inc, An Opportunity In Progress
- On The Heels Of Chemo-Approved Cancer Drugs
- For All Practical Purposes Synergy Pharmaceuticals Makes Sense
- Why Trius Therapeutics Is A Gem In The Innovative Antibiotics Market
- Inside Opko Health
- Why Some Trends Matter, Even When There Is A Hiccup
- How A Scientific Partnership Is Moving Forward With Invivo And The Miami Project
- A Different Face For Facebook
- Prolor And Other Israel-Based Medical Developments Figure Prominently On World Scene
- Sifting Through Ampio Pharmaceuticals' Pipeline
- The InVivo Effect
- ImmunoCellular: The Potential For A Cancer Vaccine
- Neostem May Have The Right Mix Of Assets To Excel In Cell Therapies
- Whether There Is Value To Be Had In 'Rudderless' Yahoo
- Why IBM Still Matters
